<DOC>
	<DOCNO>NCT02103322</DOCNO>
	<brief_summary>To characterize pharmacokinetic profile test product compare corresponding reference product adult patient , diagnose Chronic Myeloid Leukemia &amp; Gastrointestinal Stromal Tumor Fed Conditions .</brief_summary>
	<brief_title>Comparative Bioequivalence Study Adult Patients Suffering From Chronic Myeloid Leukemia &amp; Gastrointestinal Stromal Tumor Under Fed Conditions</brief_title>
	<detailed_description>To characterize pharmacokinetic profile Imatinib Mesylate tablet EQ 400 mg base Amneal Pharmaceuticals LLC , compare reference product - GLEEVECÂ® ( imatinib mesylate ) tablets 400 mg adult patient , diagnose CML GIST presently receive stable dose imatinib mesylate tablet 400 mg , assess bioequivalence .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age 18 55 year ( inclusive ) either sex Diagnosed case Philadelphia chromosome positive ( Ph+ ) CML patient chronic phase GIST presently treat imatinib 400 mg tablet . Willing give write informed consent participation study well willing able comply study visit schedule protocol requirement . Female patient child bear potential ( except complete one year since menopause go hysterectomy bilateral tubal ligation ) must negative serum pregnancy test screening , negative urine pregnancy test check housing , must nonlactating screening must agree use effective contraception ( barrier hormonal ) study period . History hypersensitivity imatinib mesylate excipients judge investigator . Patient CML receive treatment Myeloid Blast Crisis Accelerated Phase Abnormal laboratory result : History heart failure , renal insufficiency , hypereosinophilic syndrome ( HES ) , myelodysplastic syndrome ( MDS ) / myeloproliferative disease ( MPD ) acute systemic mastocytosis ( ASM ) . History therapy follow per timeline randomization : inducer CYP3A4 activity inhibitor CYP3A4 activity , within 14 day , investigational product/device within last one month Alcohol drug dependence within past one year . Blood donation/loss exceed 200 ml within last 60 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>